Story

The Full Story

Blue Moon came public in December 2020 telling a simple story: dominant brand, expanding online-to-offline distribution, deepening rural penetration, premium margins. Between FY2021 and FY2024 that story fractured: revenue growth stalled, profit fell every single year, then flipped to a HK$749M loss — the single worst result since listing — driven not by collapsing gross margins but by a 56% one-year spike in selling and distribution spend. Management recast the blow-up as a "strategic investment" in the Zhizun concentrated-detergent product line, quietly walked back the original IPO use-of-proceeds, extended the spending timeline three years, and in FY2025 cut advertising hard — losses narrowed 56% but revenue went flat, exposing the investment as fragile rather than compounding. The brand is still #1 in China on most measures; the capital discipline, the guidance, and the original growth thesis are not.

1. The Narrative Arc

Four inflection points define the arc. FY2021 exposed the first gap: revenue rose 8.6% but profit fell 22.5% as raw material costs climbed and selling expenses jumped 18.6% to defend share. FY2022 introduced non-HKFRS "adjusted EBITDA" disclosure to strip out FX losses — a presentation choice that quietly conceded GAAP profitability was deteriorating. FY2023 was the first outright revenue decline (-7.8%) alongside a 46.8% profit collapse; management began de-risking key-account receivables. FY2024 was the rupture: HK$749M loss and a management narrative that reframed the blow-up as deliberate — "strategic investments in bringing the comprehensive series of products… to reach more consumers." FY2025 was the walk-back: expenses were cut, the loss narrowed, but the promised sales growth from the 2024 investment did not materialize.

2. What Management Emphasized — and Then Stopped Emphasizing

Topic frequency across five annual filings. Higher values = greater emphasis; dashes mark themes quietly dropped.

Three patterns stand out. The Supreme-brand concentrated detergent — featured prominently in the FY2020 prospectus and still referenced in FY2021 as a sales-return drag — vanished entirely from the FY2022 report onward; management never reconciled what became of that product line. Laundry services was an explicit IPO use-of-proceeds category that management stopped discussing by FY2024 and then eliminated operationally when they reallocated capital in March 2025. Knowledge-based marketing and Zhizun moved in lockstep from barely-mentioned in FY2021–22 to the dominant motifs in FY2024–25 — the pivot from "we sell detergent" to "we educate consumers about scientific washing" coincides exactly with the period when margins were collapsing.

3. Risk Evolution

The risk discussion in MD&A reveals what management was actually worried about each year, in their own emphasis.

The risk register has rotated almost completely. Raw materials and COVID — the 2021–22 preoccupations — are now effectively retired. FX flared in FY2022 (and prompted the non-HKFRS adjusted EBITDA disclosure) and again in FY2024. Key-account credit risk peaked in FY2023 when management explicitly cut sales to credit-based customers; that channel has since shrunk from 14% of revenue (FY2021) to 4% (FY2025). The two risks rising over time — channel shift to Douyin/live-stream and cash discipline — are the unresolved ones heading into FY2026.

4. How They Handled Bad News

Management's handling of disappointments followed a pattern: absorb, reframe, measure by a new yardstick.

Three episodes illustrate the technique.

FX losses in FY2022. Net profit fell 39.7% with roughly half the drop coming from a HK$156M foreign-exchange loss on offshore RMB deposits. Management's response was to introduce an unaudited "adjusted EBITDA" that excluded FX, explicitly to "eliminate the potential impact of foreign exchange losses/(gains) which the Group consider to be non-indicative of the performance of the business." The non-HKFRS disclosure was then dropped in FY2023 when it would have made results look worse, not better.

Revenue decline in FY2023. HK$ revenue fell 7.8%. Management's framing pivoted to RMB-terms (-2.9%) and to second-half RMB growth (+4.5%), de-emphasizing the presentation-currency print.

The FY2024 loss. A HK$749M loss was described as an intentional long-term investment — yet in the same filing management reallocated HK$2.6B of unused IPO proceeds away from production capacity ("no imminent requirement to utilise a substantial portion of capital") toward more marketing, and extended the use-of-proceeds timeline from end-2025 to end-2028. A "strategic investment" that the capital plan reclassifies mid-stream is difficult to distinguish from a belated course correction.

5. Guidance Track Record

Only material promises that bore on valuation, capital allocation, or credibility are included.

Credibility score: 3.5 / 10. The brand franchise is real; the consumer rankings have held for 15+ years; gross margin has stayed in a tight 58–62% band. But at the capital-allocation and guidance layer, the record is poor: the original IPO plan was rewritten, the flagship "Supreme" product quietly disappeared, the laundry-services priority was abandoned without acknowledgment, and management's FY2024 reframe ("strategic investment") was contradicted the following year when flat revenue showed the spending hadn't earned durable growth. Investors who took FY2021–22 guidance at face value have been repeatedly asked to reinterpret past promises in light of later events.

6. What the Story Is Now

What has been de-risked. The FY2024 spending spike proved compressible: the FY2025 cost cuts landed without obvious brand damage, and the Zhizun concentrate line was productive enough to keep losses narrowing. Key-account credit exposure is now small. FX exposure is managed via USD deposits. Gross margin has been durable through the whole episode.

What still looks stretched. Three things. First, revenue growth: FY2025 was flat, and the entire FY2024 "strategic investment" has not demonstrably produced a compounding sales base. Second, cash: the deposit pile has fallen from HK$10.9B at IPO to HK$3.7B — a two-thirds reduction in five years against continuing operating losses and dividend outflows. Third, the capital plan: the reallocation of unused IPO proceeds extended delivery from 2025 to 2028, and a portion was redirected into the same selling-expense bucket that has not yet earned its keep.

What the reader should believe. The brand is genuine and the rankings are verifiable; management is competent at cost discipline when forced to apply it; and the concentrated-detergent pivot is real product innovation, not marketing fiction. What the reader should discount. Any language about "strategic investment", "long-term sales growth" from advertising, or the confidence-in-China-cleaning-market refrain — the first two were directly falsified in FY2025, and the third is a background condition, not a plan. The FY2026 test is straightforward: can revenue grow from here without a return to HK$5B+ in selling expense?